SBIO vs. ARKG
Compare and contrast key facts about ALPS Medical Breakthroughs ETF (SBIO) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
SBIO and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. SBIO is a passively managed fund by SS&C that tracks the performance of the S-Network Medical Breakthroughs Index. It was launched on Dec 31, 2014. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
SBIO vs. ARKG - Performance Comparison
Loading graphics...
SBIO vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 3.20% | 55.07% | 3.81% | 8.68% | -28.08% | -17.55% | 21.17% | 50.30% | -11.81% | 45.67% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -6.49% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Returns By Period
In the year-to-date period, SBIO achieves a 3.20% return, which is significantly higher than ARKG's -6.49% return. Over the past 10 years, SBIO has outperformed ARKG with an annualized return of 9.75%, while ARKG has yielded a comparatively lower 4.95% annualized return.
SBIO
- 1D
- 0.99%
- 1M
- 3.89%
- YTD
- 3.20%
- 6M
- 36.23%
- 1Y
- 95.78%
- 3Y*
- 26.37%
- 5Y*
- 1.76%
- 10Y*
- 9.75%
ARKG
- 1D
- 2.54%
- 1M
- -9.43%
- YTD
- -6.49%
- 6M
- -6.10%
- 1Y
- 34.11%
- 3Y*
- -3.42%
- 5Y*
- -21.16%
- 10Y*
- 4.95%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
SBIO vs. ARKG - Expense Ratio Comparison
SBIO has a 0.50% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Return for Risk
SBIO vs. ARKG — Risk / Return Rank
SBIO
ARKG
SBIO vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.92 | 0.77 | +2.16 |
Sortino ratioReturn per unit of downside risk | 3.57 | 1.38 | +2.20 |
Omega ratioGain probability vs. loss probability | 1.45 | 1.16 | +0.29 |
Calmar ratioReturn relative to maximum drawdown | 5.66 | 1.11 | +4.55 |
Martin ratioReturn relative to average drawdown | 19.94 | 2.98 | +16.96 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| SBIO | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.92 | 0.77 | +2.16 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.05 | -0.47 | +0.52 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.29 | 0.12 | +0.17 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.23 | 0.08 | +0.15 |
Correlation
The correlation between SBIO and ARKG is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
SBIO vs. ARKG - Dividend Comparison
Neither SBIO nor ARKG has paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO ALPS Medical Breakthroughs ETF | 0.00% | 0.00% | 3.55% | 0.22% | 0.00% | 0.00% | 0.00% | 0.04% | 2.79% | 1.77% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
Drawdowns
SBIO vs. ARKG - Drawdown Comparison
The maximum SBIO drawdown since its inception was -63.06%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for SBIO and ARKG.
Loading graphics...
Drawdown Indicators
| SBIO | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.06% | -83.59% | +20.53% |
Max Drawdown (1Y)Largest decline over 1 year | -15.08% | -27.51% | +12.43% |
Max Drawdown (5Y)Largest decline over 5 years | -53.67% | -80.18% | +26.51% |
Max Drawdown (10Y)Largest decline over 10 years | -63.06% | -83.59% | +20.53% |
Current DrawdownCurrent decline from peak | -13.79% | -75.76% | +61.97% |
Average DrawdownAverage peak-to-trough decline | -28.70% | -35.32% | +6.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.28% | 10.24% | -5.96% |
Volatility
SBIO vs. ARKG - Volatility Comparison
The current volatility for ALPS Medical Breakthroughs ETF (SBIO) is 12.61%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.41%. This indicates that SBIO experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| SBIO | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.61% | 13.41% | -0.80% |
Volatility (6M)Calculated over the trailing 6-month period | 22.09% | 31.90% | -9.81% |
Volatility (1Y)Calculated over the trailing 1-year period | 33.43% | 44.84% | -11.41% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.55% | 45.39% | -11.84% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 33.34% | 40.94% | -7.60% |